Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific share repurchase transaction executed on May 1, 2012, under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 305,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,444.5 pence per share; lowest price paid was 1,430.5 pence per share.
- Treasury Holdings (Settled): 517,342,927 shares (9.30% of total issued share capital).
- Treasury Holdings (Including Unsettled): 519,497,927 shares (10.29% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,046,404,827 shares.
Material Changes
The filing reports an increase in the Company's Treasury share holdings following the purchase of 305,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 10.29% when including shares purchased but not yet settled.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual reports to confirm the 9.30% to 10.29% range.
- Confirm the total issued share capital to validate the denominator used for voting rights calculations (5,046,404,827 shares in issue).
- Check subsequent filings to determine if the unsettled shares mentioned in this report were fully settled.